Search clinical trials for: BMS-986263

Total 3151 results

Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Spain, United States, Belgium, France, Italy, Netherlands, United Kingdom
Bristol-Myers Squibb

Terminated

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Tumors

United States, Belgium
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment

Unspecified Adult Solid Tumor, Protocol Specific
Bristol-Myers Squibb

Completed

Absolute Bioavailability of BMS-791325

Hepatitis C Virus Infection

United Kingdom
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Cancer

Australia, United States, Canada
Bristol-Myers Squibb

Completed

Single Ascending Dose (BMS-813160) Study

Accelerated Intimal Hyperplasia

United States
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaborators

Recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab. (TOP-FLOR)

Follicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IV

Australia
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Psoriasis

United States, Australia, Canada, Japan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Medical University of Silesia
Wojciech Wojakowski

Completed

New-DES vs BMS in SVG -1 Year Outcomes (BALTIC)

Coronary Artery Disease

Poland
Bristol-Myers Squibb

Withdrawn

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

Thrombosis

Belgium
University Health Network, Toronto

Completed

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome

Canada
ASLAN Pharmaceuticals

Completed

A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours

Malignant Solid Tumour
Bristol-Myers Squibb

Completed

Crossover Post-herpetic Neuralgia (PHN)

Post-Herpetic Neuralgia (PHN)

United States, France
Bristol-Myers Squibb

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

BMS-741672 for Diabetic Neuropathic Pain

Neuropathic Pain

United States
Bristol-Myers Squibb

Completed

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Denmark, Finland
Bristol-Myers Squibb

Completed

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb
Solvay Pharmaceuticals

Terminated

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

Obesity

United States
Bristol-Myers Squibb

Completed

BMS-599626 in Patients With Advanced Solid Malignancies

Cancer | Metastases

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Australia, Canada, Mexico
Bristol-Myers Squibb

Completed

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Withdrawn

Japanese Bridging Study Conducted in the United States

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-816336 in Healthy Male Subjects

Dyslipidemia | Diabetes Mellitus, Non-Insulin-Dependent

Australia
Bristol-Myers Squibb

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Alzheimer's Disease

United States
Bristol-Myers Squibb

Completed

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumors

Japan
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Cancer | Tumor

United States, Spain, Canada, France
Bristol-Myers Squibb

Completed

Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese (JMAD)

Healthy

Japan
Bristol-Myers Squibb

Completed

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Bristol-Myers Squibb

Completed

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Psoriasis

United States
Bristol-Myers Squibb

Withdrawn

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

Chronic Hepatitis C

Australia
Bristol-Myers Squibb

Completed

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Systemic Lupus Erythematosus | Healthy Participants

United States
Rigshospitalet, Denmark
University of Copenhagen

Recruiting

Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia (COMESS)

Mesenteric Ischemia | Stent Thrombosis | Stent Restenosis | Stent-Graft Restenosis | Stent-Graft Thrombosis | Stent-Graft Stenosis | Stent Occlusion | Bowel; Ischemic | Superior Mesenteric Atherosclerosis | Mesenteric Artery Stenosis

Denmark
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

Healthy Participants

United States
Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
Bristol-Myers Squibb

Available

Expanded Access for Repotrectinib
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Healthy Participants | Idiopathic Pulmonary Fibrosis (IPF)

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Obese But Otherwise Healthy Participants

United States
Cedars-Sinai Medical Center
Bristol-Myers Squibb

Terminated

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Urogenital Neoplasms | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, Male

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Severe Sepsis

United States
Mackay Memorial Hospital

Unknown

Stent Placement and the Risk of New-onset AF in Patients With AMI

Acute Myocardial Infarction | Atrial Fibrillation New Onset
Bristol-Myers Squibb

Completed

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Liver Fibrosis/NASH

United States
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada

Search clinical trials for: BMS-986263

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations